Profile data is unavailable for this security.
About the company
Roquefort Therapeutics PLC is a United Kingdom-based material biotech company. The Company is engaged in preclinical development of next generation medicines focused on hard-to treat cancers. The Company’s portfolio consists of over five novel patent-protected pre-clinical anti-cancer medicines. Its portfolio of medicines include Midkine antibodies with in vivo efficacy and toxicology studies, and orphan drug indication; Midkine RNA oligonucleotide therapeutics with novel anti-cancer gene editing action; Midkine mRNA therapeutics targeting solid tumors; STAT-6 siRNA therapeutics targeting solid tumors with significant in vivo efficacy, and MK cell therapy with direct and Natural Killer cell-mediated anti-cancer action. The Company has partnered with leading academic cancer research centers which complement its own in-house expertise and laboratory infrastructure.
- Revenue in GBP (TTM)0.00
- Net income in GBP-882.45k
- Incorporated2020
- Employees1.00
- LocationRoquefort Therapeutics PLC85 Great Portland Street,, First FloorLONDON W1W 7LTUnited KingdomGBR
- Phone+44 20 3918 8633
- Websitehttps://www.roquefortplc.com/
Peer analysis
| Company | Revenue (TTM) | Net income (TTM) |
|---|---|---|
| Shortwave Life Sciences PLC | 45.70k | -256.99k |
| Roquefort Therapeutics PLC | 0.00 | -882.45k |
| ValiRx Plc | 49.78k | -1.78m |
| N4 Pharma PLC | 7.07k | -1.07m |
| TheraCryf PLC | 0.00 | -2.01m |
| Cizzle Biotechnology Holdings PLC | 0.00 | -1.12m |
| Futura Medical PLC | 7.93m | -6.29m |
| OptiBiotix Health PLC | 1.15m | -191.00k |
| IXICO PLC | 6.53m | -1.65m |
